TPO and autoimmune thrombocytopenic purpura: Probably, those ITP patients, independently of the stage of the disease, who maintain stable platelet counts (50–100 × 109/L) for a period of around 2–6 months may be suitable candidates for TPO-RA discontinuation [7,8,9,12,13].